Ratings Regeneron Pharmaceuticals, Inc.

Equities

REGN

US75886F1075

Real-time Estimate Cboe BZX Other stock markets 11:08:30 2024-04-26 am EDT			5-day change	1st Jan Change
883.3 ^USD	-0.83%		-1.88%	+0.19%

02:45pm	Oppenheimer Adjusts Price Target on Regeneron Pharmaceuticals to $1,175 From $1,125	MT
Apr. 25	Regeneron Pharmaceuticals Receives a Shareholder Proposal from John Chevedden	CI

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
From a short-term investment perspective, the company presents a deteriorated fundamental situation
According to Refinitiv, the company's ESG score for its industry is good.

Strengths

Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
Thanks to a sound financial situation, the firm has significant leeway for investment.
Over the last twelve months, the sales forecast has been frequently revised upwards.
Sales forecast by analysts have been recently revised upwards.
The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
Historically, the company has been releasing figures that are above expectations.

Weaknesses

The firm trades with high earnings multiples: 24.14 times its 2024 earnings per share.
The company's "enterprise value to sales" ratio is among the highest in the world.
In relation to the value of its tangible assets, the company's valuation appears relatively high.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
REGENERON PHARMACEUTICALS, INC.	+0.20%	95.71B	B+
VERTEX PHARMACEUTICALS INCORPORATED	-3.08%	103B	B+
ARGENX SE	+0.90%	22.02B	B
BIONTECH SE	-17.05%	20.9B	B+
GENMAB A/S	-9.30%	17.85B	A-
WUXI APPTEC CO., LTD.	-42.83%	16.21B	A-
BEIGENE, LTD.	-15.83%	15.52B	B
NEUROCRINE BIOSCIENCES, INC.	+5.00%	13.86B	C+
SAREPTA THERAPEUTICS, INC.	+31.89%	12.04B	C+
LEGEND BIOTECH CORPORATION	-26.08%	8.08B	D

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes